Focus Sector: Autoimmune Research & Funding Analysis

MISSION: The Flare audits unpublished, shelved, withdrawn, and terminated clinical trial data in the autoimmune and oncology sectors. We translate raw data into transparent briefings for patients, families, advocacy groups, and independent researchers.

Autoimmune diseases collectively affect an estimated 23.5 to 50 million Americans, depending on how many of the 140-plus recognized conditions are included in the count—yet NIH research funding for this category has remained locked at approximately 2.8 percent of total NIH obligations for over a decade. This briefing examines three compounding problems: the documented rise in autoimmune biomarkers across the U.S. population, the structural funding disparity relative to disease burden, and the specialty siloing that fragments research dollars and delays translational progress. The Flare launches with this foundational audit to establish the evidence baseline against which all future trial data will be evaluated.

The Scope. Autoimmune diseases are not rare in any meaningful clinical or epidemiological sense. The NIH's own estimates, drawn from a 24-disease analysis published in 2005, placed the affected U.S. population at 14.7 to 23.5 million. The American Autoimmune Related Diseases Association (now the Autoimmune Association) has long argued that when all 100-plus recognized autoimmune conditions are aggregated, the figure is closer to 50 million. The NIH-Wide Strategic Plan for Autoimmune Disease Research (Fiscal Years 2026–2030), released in July 2025, references the range of 23.5 to 50 million Americans affected by more than 140 identified autoimmune conditions.

The Rise of Antinuclear Antibodies. A peer-reviewed study published in April 2020 in Arthritis and Rheumatology—conducted by researchers at the NIH National Institute of Environmental Health Sciences (NIEHS)—documented a statistically significant increase in antinuclear antibody (ANA) prevalence across the U.S. population over a 25-year span. ANA is the primary blood biomarker used to screen for systemic autoimmunity.

The study measured ANA prevalence across three time periods using 14,211 participants age 12 and older. ANA prevalence rose from 11.0% in 1988–1991, to 11.5% in 1999–2004, to 15.9% in 2011–2012. These percentages correspond to estimated affected populations of approximately 22 million, 27 million, and 41 million individuals, respectively. Among adolescents aged 12–19, the increase was the sharpest of any demographic group—rising to a nearly three-fold increase by the 2011–2012 period.

The Environmental Exposome. Because the human genome does not change meaningfully over a 25-year period, genetic predisposition alone cannot account for the rate at which ANA prevalence and autoimmune disease incidence are increasing. Researchers are directing attention toward "the exposome"—the cumulative lifetime sum of all non-genetic exposures an individual encounters, including chemical toxins, dietary composition, microbial environments, psychological stress, and viral triggers. Post-viral immune dysregulation is among the environmental variables under active scientific investigation as a potential trigger for autoimmune onset in genetically susceptible individuals.

The following table compares NIH annual research funding against estimated U.S. patient burden for three disease categories.

The disparity is structural, not incidental. A 2022 report by the National Academies of Sciences, Engineering, and Medicine (NASEM) confirmed that NIH investment in autoimmune disease research remained essentially flat at approximately 2.8 percent of total NIH obligations from 2008 through 2020.

NIH investment in autoimmune research has grown modestly in absolute terms—from $822 million in 2014 to more than $1 billion by 2024—but critics note that this growth has not kept pace with total NIH budget expansion or the rising documented burden of the disease category.

The funding disparity is not a product of deliberate neglect. It is a product of institutional architecture—specifically, the way medical research, clinical practice, and federal budget allocation are organized by organ system and specialty discipline rather than by immune mechanism.

The Specialty Silo. A patient diagnosed with cancer enters a unified referral system: oncology. A patient with an autoimmune condition may be routed to rheumatology, gastroenterology, dermatology, pulmonology, or neurology—depending on which organ the immune system is targeting. There is no unified clinical entry point, and there has historically been no unified research infrastructure to match.

Scattershot Funding. Until the establishment of the Office of Autoimmune Disease Research (OADR) in 2023, NIH autoimmune research dollars were distributed across 13 or more separate Institutes and Centers with no central coordinating budget. Research dollars for lupus, multiple sclerosis, celiac disease, type 1 diabetes, and inflammatory bowel disease were each administered through different funding pathways, often without coordination.

Repurposed Therapeutics. One measurable consequence of underfunding and siloing is the pattern of therapeutic hand-me-downs. Rituximab, a monoclonal antibody that depletes B cells, was originally developed and approved for B-cell lymphoma before researchers began studying its application in rheumatoid arthritis and systemic lupus erythematosus. Similarly, CAR-T cell therapy was developed through oncology pipelines targeting hematologic malignancies before researchers began adapting it for autoimmune applications. As of late 2024, 116 clinical trials were evaluating CAR-T cell approaches against autoimmune conditions. The science is proving promising, but the research pathway ran through cancer biology first, not immunology.

Antinuclear Antibody (ANA). ANA is the standard first-line blood test used to screen for systemic autoimmune diseases. The test detects immunoglobulins (antibodies) that target antigens within the cell nucleus. A positive ANA result does not confirm a diagnosis of autoimmune disease—ANA positivity occurs in a subset of healthy individuals—but when combined with clinical symptoms and additional serologic testing, a positive result is considered a significant diagnostic signal. The standard clinical threshold for a positive result is a titer of 1:80 or higher using indirect immunofluorescence on HEp-2 cells.

When research funding is constrained and infrastructure is siloed, marginal data gets abandoned. If a drug candidate demonstrates a preliminary efficacy signal but requires a large, capital-intensive Phase 3 expansion to confirm it, small and mid-size biotech sponsors—operating under finite runway—are forced to terminate the program before that confirmation is achieved. The trial closes. The data enters a registry with a "terminated" status. The mechanism is not published in a peer-reviewed journal. The families of patients who might have enrolled never learn it existed.

The Flare audits these abandoned data points. We review terminated, withdrawn, and unpublished clinical trial records in the autoimmune and oncology sectors. We cross-reference sponsor filings, SEC disclosures, and registry entries. We present the findings as factual, sourced, non-speculative briefings—without editorial promotion of any therapeutic approach and without medical advice of any kind.

Legal Disclaimer: The Flare is an independent investigative journalism outlet. We are not medical providers, clinical trial sites, or financial advisors. The information published in this briefing is for educational and journalistic purposes only and does not constitute medical advice. Always consult a qualified medical professional for health-related decisions. The Flare does not endorse any pharmaceutical product, therapeutic approach, or clinical trial sponsor.